US Patent 7297511 Interferon alpha: remodeling and glycoconjugation of interferon alpha
Patent 7297511 was granted and assigned to Neose Technologies Inc. on November, 2007 by the United States Patent and Trademark Office.
All edits
Edits on 16 Sep, 2023
Golden AI
Edits made to:
Infobox (+6 properties)
Infobox
Patent Inventor Names
Caryn Bowe0
David Hakes0
David Zopf0
Robert Bayer0
Shawn DeFrees0
Xi Chen0
Edits on 1 Sep, 2023
Golden AI
Edits made to:
Article (+247 characters)
Article
Patent abstract
The invention includes a multitude of methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.
Edits on 22 Jul, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 21 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07297511 Interferon alpha: remodeling and glycoconjugation of interferon alpha US Patent 7297511 Interferon alpha: remodeling and glycoconjugation of interferon alpha
Infobox
Patent Number
072975110
Patent Number
72975110
Edits on 24 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
072975110
Date of Patent
November 20, 2007
0Patent Application Number
104110490
Date Filed
April 9, 2003
0Official Website
Patent Primary Examiner
Edits on 17 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 23 Nov, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07297511 Interferon alpha: remodeling and glycoconjugation of interferon alpha
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07297511
Date of patent
November 20, 2007
Patent application number
10411049
Date Filed
April 9, 2003
Patent primary examiner
Find more entities like US Patent 7297511 Interferon alpha: remodeling and glycoconjugation of interferon alpha
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
